organization · Reporting owner
KNIGHT THERAPEUTICS INTERNATIONAL SA
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Synergy CHC Corp.SNYR · Entity 8555 | 10% owner | October 22, 2024 | October 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Synergy CHC Corp.
Report date October 22, 2024 · Filed October 22, 2024
Jointly reported with Knight Therapeutics Inc.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | IndirectHeld through Knight Therapeutics International SA, a subsidiary of Knight Therapeutics Inc. | 1,482,844 |
Reported balance
Holding disclosure · report date 2024-10-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,482,844 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
60 DEGREES PHARMACEUTICALS, INC.
Report date July 28, 2023 · Filed April 03, 2024
Jointly reported with Knight Therapeutics Inc.
Section 16 reporting ended · disclosed 2024-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.0001 par value per share ("Common Shares")SEC Table I · non-derivative | IndirectBy Knight Therapeutics International S.A. | 1,153,897 |
Reported balance
After 2023-07-28 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-07-28 · Conversion · Acquired 45,560 · Balance 1,153,897 F1: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock. F2: After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. F3: None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares. F4: Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose. |
| Series A Non-Voting Convertible Preferred StockSEC Table I · non-derivative | IndirectBy Knight Therapeutics International S.A. | 78,803 |
Reported balance
After 2023-07-28 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-07-28 · Conversion · Disposed 2,162 · Balance 78,803 F1: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock. F2: After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. F3: None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares. F4: Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock.
F2: After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer.
F3: None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares.
F4: Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2023 Filed Apr 3, 2024 18:00 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | ConversionSeries A Non-Voting Convertible Preferred Stock | 2,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-24-017682 · form4.xml · nonDerivative · entry 2 Knight Therapeutics Inc · CIK 0001756235 · Former 10% Owner KNIGHT THERAPEUTICS INTERNATIONAL SA · CIK 0001632373 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Knight Therapeutics International S.A. Disclosed balance after: 78,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock. F2 · balance_after: After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. F3 · balance_after: None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares. F4 · ownership.direct: Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose. Read SEC document |
| July 28, 2023 Filed Apr 3, 2024 18:00 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | ConversionCommon Stock, $0.0001 par value per share ("Common Shares") | 45,560 | $4.75 | $216,182.20 |
DisclosureSEC source: 0001140361-24-017682 · form4.xml · nonDerivative · entry 1 Knight Therapeutics Inc · CIK 0001756235 · Former 10% Owner KNIGHT THERAPEUTICS INTERNATIONAL SA · CIK 0001632373 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Knight Therapeutics International S.A. Disclosed balance after: 1,153,897 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock. F1 · price: On July 28, 2023, 60 Degrees Pharmaceuticals, Inc. (the "Issuer"), at its sole discretion, converted 2,162 shares of Series A Non-Voting Convertible Preferred Stock (the "Preferred Stock") held by Knight Therapeutics International S.A., an Uruguayan corporation ("Knight Subsidiary") into 45,560 Common Shares, at a conversion price equal to the 10 day volume weighted average price of the Common Shares immediately prior to the conversion. The Preferred Stock has a floating conversion price. Only the Issuer can cause shares of Preferred Stock to be converted into Common Shares. The conversion price of the Preferred Stock is determined in respect of the shares of Preferred Stock that are actually converted into Common Shares by the Issuer at the time of such conversion. The timing of conversion of any shares of Preferred Stock occurrence is outside of the control of the holder of the Preferred Stock. F2 · balance_after: After giving effect to the transaction reported on this Form 4, Knight Subsidiary directly beneficially owns 1,153,897 Common Shares, corresponding to 9.97% ownership interest based on 11,570,578 Common Shares issued and outstanding as of April 1, 2024, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. Knight Therapeutics Inc., a Canadian corporation ("Knight Parent" and collectively with Knight Subsidiary, the "Reporting Persons") indirectly beneficially owns 1,153,897 Common Shares, and 78,803 Preferred Stock convertible only at the sole discretion of the Issuer. F3 · balance_after: None of the Reporting Persons can cause the Preferred Stock to be converted into Common Shares, and the Reporting Persons have no control over the occurrence or timing of a conversion of the Preferred Stock by the Issuer into Common Shares. The shares of Preferred Stock are not "derivative securities." The Reporting Persons do not beneficially own any of the Common Shares underlying the Preferred Stock until such time as the Issuer actually converts shares of Preferred Stock held by the Reporting Persons into Common Shares. F4 · ownership.direct: Knight Parent is the sole owner of Knight Subsidiary and, as a result, may be deemed the beneficial owner for purposes of Securities Exchange Act of 1934 (the "Act") of any securities of the Issuer beneficially owned by Knight Subsidiary. Knight Parent disclaims beneficial ownership over all of the Common Shares beneficially owned by Knight Subsidiary, other than for the purpose of determining obligations under the Act, and the filing of this Form 4 shall not be deemed an admission that Knight Parent is the beneficial owner of such securities for any other purpose. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 12:51 UTC Amendment | Synergy CHC Corp. SNYR · Entity 8555 | OtherStock Options · Derivative | 1 | Not disclosed Strike: $0.25 | Not disclosed |
DisclosureSEC source: 0001019056-16-001718 · synergy_4a.xml · derivative · entry 4 Knight Therapeutics (Barbados) Inc. · CIK 0001632373 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 1,000,000 shares Expires 2025-12-14 F1 · kind: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. F1 · price: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 12:51 UTC Amendment | Synergy CHC Corp. SNYR · Entity 8555 | OtherWarrants · Derivative | 1 | Not disclosed Strike: $0.49 | Not disclosed |
DisclosureSEC source: 0001019056-16-001718 · synergy_4a.xml · derivative · entry 3 Knight Therapeutics (Barbados) Inc. · CIK 0001632373 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 4,547,243 shares Expires 2025-11-12 F1 · kind: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. F1 · price: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 12:51 UTC Amendment | Synergy CHC Corp. SNYR · Entity 8555 | OtherWarrants · Derivative | 1 | Not disclosed Strike: $0.34 | Not disclosed |
DisclosureSEC source: 0001019056-16-001718 · synergy_4a.xml · derivative · entry 2 Knight Therapeutics (Barbados) Inc. · CIK 0001632373 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 3,584,759 shares Expires 2025-01-22 F1 · kind: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. F1 · price: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. Read SEC document |
| December 22, 2016 Filed Dec 23, 2016 12:51 UTC Amendment | Synergy CHC Corp. SNYR · Entity 8555 | OtherCommon Stock | 7,500,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001019056-16-001718 · synergy_4a.xml · nonDerivative · entry 1 Knight Therapeutics (Barbados) Inc. · CIK 0001632373 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,645,812 F1 · kind: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. F1 · price: The Reporting Person received 7,500,000 common shares in the capital of the Issuer as consideration for the cancellation of the following derivative securities: (i) a share purchase warrant dated January 22, 2015 exercisable into 3,584,759 common shares of the Issuer, (ii) a share purchase warrant dated November 12, 2015 exercisable into 4,547,243 common shares of the Issuer, and (iii) stock options with respect to 1,000,000 common shares of the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.